AgomAb Therapeutics

Franklin Rooseveltlaan 348 126

9000 Gent

BE

AgomAb Therapeutics

Foundation date

2017

Sector

#Biotechnology - Therapeutics

Subsector

Therapeutic areas

AgomAb is developing molecular therapies for the regeneration of damaged tissues. Our unique agonistic monoclonal antibody molecules (“agomAbs”) stimulate molecular and cellular repair mechanisms that have the potential to restore organ function in patients with fibrotic, inflammatory, autoimmune and degenerative diseases.

Upcoming events

Latest news

  • Mithra announces topline results for COVID-19 Phase II Study

    1 day ago

  • Biocartis announces restart of its high-throughput cartridge manufacturing line

    Thursday September 23rd 2021

  • Rewind Therapeutics appoints Anja Harmeier, PhD, MBA, as Chief Executive Officer

    Wednesday September 22nd 2021